Draft guidance published for an immunotherapy treatment that could prevent blood cancer from returning in adults who've ...
Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback